ATE273705T1 - Caspase-hemmer - Google Patents
Caspase-hemmerInfo
- Publication number
- ATE273705T1 ATE273705T1 AT00961242T AT00961242T ATE273705T1 AT E273705 T1 ATE273705 T1 AT E273705T1 AT 00961242 T AT00961242 T AT 00961242T AT 00961242 T AT00961242 T AT 00961242T AT E273705 T1 ATE273705 T1 AT E273705T1
- Authority
- AT
- Austria
- Prior art keywords
- derivative
- present
- caspases
- esters
- pharmaceutically acceptable
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title abstract 3
- 108010076667 Caspases Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000002547 isoxazolines Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR1999/000561 WO2001021599A1 (en) | 1999-09-17 | 1999-09-17 | Caspase inhibitor |
| KR10-1999-0048608A KR100399361B1 (ko) | 1999-11-04 | 1999-11-04 | 캐스파제 억제제 함유 치료제 조성물 |
| PCT/KR2000/001047 WO2001021600A1 (en) | 1999-09-17 | 2000-09-18 | Caspase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE273705T1 true ATE273705T1 (de) | 2004-09-15 |
Family
ID=26634563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00961242T ATE273705T1 (de) | 1999-09-17 | 2000-09-18 | Caspase-hemmer |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1212309B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4195561B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1137888C (cg-RX-API-DMAC10.html) |
| AT (1) | ATE273705T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU7322300A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2388564C (cg-RX-API-DMAC10.html) |
| DE (1) | DE60013147T2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2001021600A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| US7026111B2 (en) * | 2001-10-15 | 2006-04-11 | Beckman Coulter, Inc. | Methods and reagents for improved cell-based assays |
| KR100594544B1 (ko) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
| KR100774999B1 (ko) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
| EP1746167A1 (en) * | 2005-07-20 | 2007-01-24 | Apoxis SA | Method for the identification of compounds susceptible to inhibit inflammation |
| WO2009013293A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Substituted cyclohexanecarboxamides useful as bace inhibitors |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| TW201919712A (zh) | 2017-08-10 | 2019-06-01 | 法商塞勒尼斯醫療控股公司 | 運送子(cargomers) |
| TWI906428B (zh) * | 2020-12-10 | 2025-12-01 | 南韓商Ｌｇ化學股份有限公司 | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ283564B6 (cs) * | 1993-11-26 | 1998-05-13 | Pfizer Inc. | 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi |
| JP2818820B2 (ja) * | 1993-11-26 | 1998-10-30 | ファイザー・インク． | 抗炎症剤としての３−アリール−２−イソオキサゾリン類 |
| AU684887B2 (en) * | 1994-03-09 | 1998-01-08 | Pfizer Inc. | Isoxazoline compounds as inhibitors of TNF release |
| BR9712987A (pt) * | 1996-10-11 | 2000-04-18 | Warner Lambert Co | Inibidores de enzima de conversão de interleucina-1beta de sulfonamida |
| JPH11180891A (ja) * | 1997-12-25 | 1999-07-06 | Dai Ichi Seiyaku Co Ltd | 抗細胞死剤 |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
-
2000
- 2000-09-18 JP JP2001524979A patent/JP4195561B2/ja not_active Expired - Fee Related
- 2000-09-18 AU AU73223/00A patent/AU7322300A/en not_active Abandoned
- 2000-09-18 EP EP00961242A patent/EP1212309B1/en not_active Expired - Lifetime
- 2000-09-18 CA CA002388564A patent/CA2388564C/en not_active Expired - Fee Related
- 2000-09-18 DE DE60013147T patent/DE60013147T2/de not_active Expired - Lifetime
- 2000-09-18 CN CNB008137056A patent/CN1137888C/zh not_active Expired - Fee Related
- 2000-09-18 AT AT00961242T patent/ATE273705T1/de not_active IP Right Cessation
- 2000-09-18 WO PCT/KR2000/001047 patent/WO2001021600A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60013147D1 (en) | 2004-09-23 |
| JP2003509502A (ja) | 2003-03-11 |
| WO2001021600A1 (en) | 2001-03-29 |
| DE60013147T2 (de) | 2005-08-11 |
| EP1212309A1 (en) | 2002-06-12 |
| CN1137888C (zh) | 2004-02-11 |
| EP1212309A4 (en) | 2002-11-27 |
| JP4195561B2 (ja) | 2008-12-10 |
| CN1377344A (zh) | 2002-10-30 |
| EP1212309B1 (en) | 2004-08-18 |
| CA2388564C (en) | 2007-11-06 |
| CA2388564A1 (en) | 2001-03-29 |
| AU7322300A (en) | 2001-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010435A (es) | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. | |
| NO179582C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive hydroksamsyre- og N-hydroksyurinstoff-derivater | |
| DK0672041T3 (da) | Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf | |
| MXPA04006553A (es) | Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. | |
| PL360495A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| UY25148A1 (es) | Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid) | |
| DE60140491D1 (de) | Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts | |
| BG108806A (en) | IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF | |
| UA84407C2 (en) | Acetyl 2-hydroxy-1,3 diaminoalkanes | |
| DE60021873D1 (de) | Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält. | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| MEP54608A (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| EP1212309A4 (en) | CASPASE INHIBITORS | |
| EA199900057A1 (ru) | Ингибиторы матриксных металлопротеиназ | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| TW200407133A (en) | Novel PPARα and PPARγ agonists | |
| NO20050667L (no) | N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes | |
| ATE258916T1 (de) | Ungesättigte hydroximsäurederivate als parp inhibitoren | |
| FI974444A0 (fi) | N-hydroksiureayhdisteitä anti-inflammatorisina aineina | |
| MX2024014831A (es) | Derivados de acido sialico y metodos de uso de los mismos | |
| DE69103773D1 (de) | Derivate von hydroxaminsäure die lipoxygenase hemmen. | |
| DE60228968D1 (de) | Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
| AR026241A1 (es) | Empleo de carbinoles 2-imidazolil substituidos para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas porestados isquemicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |